OPKO HEALTH INC (OPK)
Health Care · Biopharmaceuticals and Clinical Diagnostics · NASDAQ
OPKO Health is a diversified healthcare company balancing a proprietary pharmaceutical and vaccine pipeline with a commercial clinical laboratory testing business.
What OPKO HEALTH INC does
OPKO Health is a biopharmaceutical and diagnostics company that operates through two primary segments: pharmaceuticals and laboratory services. The company develops and commercializes drugs and vaccines, and it provides clinical laboratory testing services. Its portfolio includes diagnostic products like the 4Kscore test and therapeutic assets such as NGENLA (somatrogon) and Rayaldee.
Themes: biopharmaceuticals, clinical laboratory testing, vaccine development, endocrinology / growth hormone disorders, diagnostics / prostate cancer testing
Fundamentals
- Price$1.48 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+7.2% 2025-08-21 close $1.38 → 2026-08-21 close $1.48
- P/En/a negative earnings
- Net margin-23.9% as of 2026-08-24
- Gross margin+38.0% as of 2026-08-24
- ROE-5.9% as of 2026-08-24
- Debt / equity0.30 as of 2026-08-24
- Revenue growth (YoY)-29.0% as of 2026-08-24
- Revenue CAGR (3y)-15.5% SEC XBRL
- Beta1.51 as of 2026-08-24
- Last reported earnings2026-07-27 SEC EDGAR Form 8-K (Item 2.02)
How OPK compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OPKO HEALTH INC looks technically
OPKO HEALTH INC (OPK) is trading 15.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 34 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 19 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 15.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.38 | $1.38 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.28 | $1.28 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 1.28. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 34 trading days ago — a "golden cross", a bullish long-term signal | 34 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 15.2% above | +15.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 37.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 61.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.28 to $1.52) — its "stochastic" reading is 83 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 83.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $1.73 | $1.73 |
|---|---|---|
| From the 52-week high | it is 14.5% below its 52-week high (its highest price of the past year) | -14.4% |
| Above the 52-week low | it is 51.5% above its 52-week low (its lowest price of the past year) | +51.5% |
| Below the 52-week high | it is 14.5% below its highest point of the past year | 14.4% |
| Since a 20-day breakout | it made a new 20-day high about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $19.20 (set on 2015-06-03) | $19.20 |
| Given back of the 52-week move | over the past year its closes ranged ($1.10 to $1.65), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.29 to $1.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.9% |
| From the all-time high | it is 92.3% below its all-time high | -92.3% |
| Nearest price level | it is trading 3.5% above a support level at $1.43 — a price it turned at six times since 2024-09-23, most recently on 2026-01-22. Since 2024-08-21 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.5% |
| All-time low | its lowest closing price on record is $0.35 (set on 2005-07-28) | $0.35 |
| Above the all-time low | it is 322.9% above its all-time low | +322.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0724 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0724 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.22 and $1.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.22 – $1.38 – $1.55 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (15.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 11.3% above the previous close 18 sessions ago and has not traded back through the level it left behind at 1.24 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +11.3% |
| Gap filled | a 2.2% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 20.0 percentage points (the stock gained 22.3% while the market gained 2.3%) | +20.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 12.5 percentage points (the stock gained 15.6% while the market gained 3.1%) | +12.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.3 percentage points (the stock gained 23.3% while the market gained 11.1%) | +12.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.2 percentage points (the stock gained 7.2% while the market gained 20.5%) | -13.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.8% of the share price. | +7.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.31 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +13.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-27 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $1.47 — a volume-weighted average of daily closes over 20 sessions, not a true tick-by-tick VWAP. | +0.6% |
Price levels it has turned at before
OPK last closed at $1.48 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.43 | Support | 3.5% below the last close | turned there six times · 2024-09-23 to 2026-01-22 |
| $1.54 | Resistance | 4.4% above the last close | turned there four times · 2025-01-13 to 2026-06-05 |
| $1.38 | Support | 6.9% below the last close | turned there four times · 2024-11-07 to 2026-01-08 |
| $1.35 | Support | 8.9% below the last close | turned there twice · 2025-04-10 to 2026-06-22 |
| $1.61 | Resistance | 9.1% above the last close | turned there three times · 2024-10-29 to 2026-06-26 |
| $1.73 | Resistance | 16.6% above the last close | turned there five times · 2024-08-30 to 2026-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $1.28.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.84 and $2.19 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $1.28.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · in a strong, established uptrend (ADX) · beating the market · At the top of its 14-day range (stochastic above 80) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$4.38 range $3.00 – $8.50; median $3.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OPK
- Consensus EPS estimate-$0.07 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and potential inability to achieve or sustain profitability and cash flow.","Dependence on reimbursement from government and private payors for laboratory services and pharmaceutical products.","Risks related to clinical development, regulatory approval processes, and commercialization of new drug candidates."]
What changed in the latest 10-Q
AI-assisted comparison of OPK's 10-Q filed 2026-04-28 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 44 (filed 2025-10-29) to 42 (filed 2026-04-28)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 58 (filed 2025-10-29) to 52 (filed 2026-04-28)
- Page number for 'Controls and Procedures' changed from 59 (filed 2025-10-29) to 53 (filed 2026-04-28)
- Page number for 'PART II. OTHER INFORMATION' changed from 59 (filed 2025-10-29) to 53 (filed 2026-04-28)
- Page number for 'Legal Proceedings' changed from 59 (filed 2025-10-29) to 53 (filed 2026-04-28)
- Notes:
- These are table of contents entries with page numbers; the actual substantive content of these sections is not provided in the source texts
Risk Factors
- Added:
- Risk factor added in 2026 filing: 'Food and Drug Administration' explicitly named instead of general 'FDA' reference
- Reworded:
- Reference to '10-K for the year ended December 31, 2025' in newer filing (filed 2026-04-28) versus '10-K for the year ended December 31, 2024' in older filing (filed 2025-10-29)
- Final risk factor changed from 'changes in personnel and funding for government agencies, including the FDA, could negatively impact our business and financial condition' (older filing) to 'changes in personnel and funding for government agencies, including the Food and Drug Administration, could negatively impact our business and financial condition' (newer filing)
- Notes:
- The two filings cover different reporting periods (Q1 2026 ending March 31, 2026 versus Q3 2025 ending September 30, 2025), so risk factors may differ due to temporal context rather than substantive policy changes
- Financial statement data is not comparable as it reflects different reporting dates and periods
- The Condensed Consolidated Statements of Operations sections are truncated in both source texts and cannot be fully compared
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days1 buy ($11350) · 0 sells — 1 buying insider
Most recent open-market transaction: 2026-03-20. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OPK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OPK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 48,119,533
- Reported value $54,856,267
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OPK had 32,883,700 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OPK had 4.41% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.39 days to cover at the same settlement.
- Reported short interest (shares) 32,883,700
- Short interest (% of shares outstanding) 4.41%
- Prior settlement (shares) 33,644,789
- Reported change -2.26%
- Days to cover (reported) 5.39
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OPK vs…
Frequently asked questions
What does OPKO HEALTH INC (OPK) do?
OPKO Health is a biopharmaceutical and diagnostics company that operates through two primary segments: pharmaceuticals and laboratory services. The company develops and commercializes drugs and vaccines, and it provides clinical laboratory testing services. Its portfolio includes diagnostic products like the 4Kscore test and therapeutic assets such as NGENLA (somatrogon) and Rayaldee.
What sector is OPKO HEALTH INC (OPK) in?
OPKO HEALTH INC (OPK) is classified in the Health Care sector. Its industry is Biopharmaceuticals and Clinical Diagnostics. It trades on NASDAQ.
Who are OPKO HEALTH INC's (OPK) competitors?
Notable peers of OPKO HEALTH INC (OPK) include Quest Diagnostics, Labcorp, Pfizer, Novo Nordisk and Eli Lilly. This peer set is informational only — not financial advice.
Is OPKO HEALTH INC (OPK) overbought or oversold right now?
OPKO HEALTH INC (OPK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OPK come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.